Neumora Enters New Era Under CEO Pinto, Bets on Key Pipeline Milestones

WATERTOWN, MA – August 14, 2026 – Neumora Therapeutics, a clinical-stage biopharmaceutical company aiming to redefine neuroscience drug development, is navigating a pivotal juncture marked by a strategic leadership overhaul and a series of high-stakes clinical milestones. In its second-quarter 2026 update, the company announced the appointment of Joshua Pinto, Ph.D., as its new chief executive officer, alongside promising advancements in its pipeline targeting obesity, Alzheimer’s disease agitation, and schizophrenia. This progress is backstopped by a disciplined financial strategy that extends its operational runway into the third quarter of 2027, setting the stage for a transformative period for the company and its investors.

A Strategic Shift in the C-Suite

In a significant move signaling a new phase of growth, Neumora has elevated Joshua Pinto, Ph.D., to the role of president and chief executive officer. Dr. Pinto, who has been with the company since 2021 and previously served as president and chief financial officer, has been a key architect of the company’s pipeline and fundraising strategy. His background, combining a Ph.D. in Neuroscience with deep biotechnology industry experience, positions him to steer the company as its scientific programs mature.

“It has been a privilege to work alongside Paul and the exceptional team at Neumora, and I’m honored to step into the role of CEO,” said Dr. Pinto. “Our programs target some of the greatest medical challenges of our generation, and our commitment to developing innovative treatments for patients is deeply personal to me and at the core of everything we do.”

Co-founder Paul L. Berns, a seasoned industry veteran with a track record of leading companies to successful acquisitions, transitions to the role of Executive Chair. This move ensures his strategic guidance and extensive industry network remain integral to Neumora’s long-term vision. “I’m incredibly proud of what our team has accomplished and confident that Josh is the right leader to guide the company through its next phase of growth,” Berns stated, highlighting the company’s evolution over the last 18 months.

Further strengthening its clinical leadership, the company also appointed Doron Sagman, M.D., as its new chief medical officer. Dr. Sagman brings over two decades of executive experience from firms like Eli Lilly, providing critical expertise in clinical development and regulatory strategy as Neumora’s candidates advance toward later-stage trials.

A Pipeline Bracing for Crucial Readouts

With the recent discontinuation of its navacaprant program for major depressive disorder casting a long shadow, the focus has intensified on the remaining assets in Neumora’s pipeline. The company is now banking on three key programs, each with significant data readouts and milestones expected before the end of 2026.

First is NMRA-215, a potential best-in-class oral NLRP3 inhibitor for obesity and cardiometabolic disease. This candidate operates on a novel mechanism, targeting neuroinflammation in the brain's hypothalamus to modulate appetite signals. Favorable preclinical data showed not only significant weight loss as a standalone therapy but also additive effects when combined with semaglutide, the active ingredient in blockbuster drugs like Ozempic and Wegovy. After overcoming an earlier toxicology setback, Neumora plans to submit an Investigational New Drug (IND) application in the fourth quarter of 2026 and initiate a Phase 1 study by year-end. Success here would position Neumora in the highly competitive but immensely lucrative obesity market.

Next, NMRA-511 targets agitation in Alzheimer’s disease, a debilitating symptom with high unmet need. The vasopressin 1a receptor (V1aR) antagonist is set to have data reported from a Multiple Ascending Dose (MAD) expansion cohort in the fourth quarter of 2026. This data will be critical in shaping the design of a Phase 2 study, which the company also aims to initiate by the end of the year.

Finally, NMRA-898 represents a novel approach to treating schizophrenia. As an M4 positive allosteric modulator (M4 PAM), it aims to deliver antipsychotic effects without the harsh side effects associated with traditional dopamine receptor antagonists, which often lead to high rates of medication non-adherence. With a human half-life suggesting potential for once-daily dosing and a Phase 1 data readout expected in the second half of 2026, NMRA-898 could offer a much-needed alternative for millions of patients.

Balancing Innovation and the Bottom Line

Underpinning these ambitious clinical plans is a clear focus on financial prudence. Neumora reported a cash and cash equivalents position of $116.8 million as of June 30, 2026. While this represents a significant burn from the $182.5 million held at the end of 2025, the company projects this runway will fund operations into the third quarter of 2027—a crucial window to achieve its upcoming clinical milestones.

This extended runway is the result of what the company calls “disciplined execution.” Research and development (R&D) expenses for the quarter fell to $29.3 million from $38.7 million in the prior year, while general and administrative (G&A) expenses also decreased to $12.9 million from $15.3 million. This strategic reduction in spend, coupled with an improved net loss of $43.1 million compared to $52.7 million in Q2 2025, demonstrates a concerted effort to manage resources effectively while advancing high-priority programs.

For a clinical-stage biotech without revenue, managing cash burn is paramount. This financial discipline provides investors with a degree of stability and confidence that the company has the resources to see its key programs through their next inflection points without imminent dilution.

Market Perspective and the Path Forward

The market has reacted with cautious optimism to Neumora’s update. The company’s stock saw a modest uptick following the announcement, reflecting an appreciation for the extended cash runway and concrete pipeline timelines. Analyst sentiment remains broadly positive, with a consensus “Buy” rating and an average price target of $6.57, suggesting significant upside from its current trading level. Many see the upcoming data readouts as the primary catalysts that could unlock substantial value.

However, the memory of the navacaprant failure lingers, serving as a stark reminder of the inherent risks in neuroscience drug development. Neumora's leadership must now execute flawlessly on its clinical and regulatory strategy. The series of data readouts expected in the second half of 2026 for NMRA-511 and NMRA-898, along with the successful initiation of the NMRA-215 study, will be the ultimate arbiters of the company’s new direction. For investors and patients alike, the next six months will be a defining period for Neumora Therapeutics.